AstraZeneca PLC (LON:AZN) said the timeline for its closely-followed MYSTIC clinical trial, treating patients with late-stage lung cancer has been pushed back.
Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first.
MYSTIC deployed Imfinzi, developed by AZ’s US biotechnology arm MedImmune, in combination with tremelimumab, an antibody treatment also created by the company’s American research arm.
The open-label efficacy assessment was designed to test the combination therapy against the current gold standard chemotherapy for patients with a form of locally-advanced or metastatic non-small cell lung cancer.
The trial is being conducted in 167 centres across 17 countries, including the US, Canada, Europe, and parts of Asia.